Chain Bridge I

Chain Bridge I has amended its Senior Note with C/M Capital Master Fund LP, extending the maturity date and modifying default conditions, while also issuing new notes for general corporate purposes.

Chain Bridge I shareholders approved an extension of the deadline to complete an initial business combination to November 15, 2026, alongside significant share redemptions.

Chain Bridge I has issued an unsecured, non-interest bearing promissory note for $1.25 million to C/M Capital Master Fund LP to fund its initial business combination and general corporate purposes.

Chain Bridge I has entered into an agreement with Fulton AC I LLC to extend its business combination deadline to November 15, 2026, supported by new capital contributions to the trust account.

Chain Bridge I and CommLoan have signed a non-binding Letter of Intent for a business combination, aiming to create a new public company focused on commercial real estate fintech.

Chain Bridge I files an amendment to its previous 8-K report to include the auditor letter from Frank, Rimerman + Co. LLP, following the termination of their engagement and the engagement of RBSM, LLP.

Chain Bridge I's latest quarterly report reveals a significant working capital deficit and continued uncertainty regarding its business combination, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I reports a net loss of $436,659 for Q1 2026 while continuing to pursue a business combination with Phytanix Bio.

Chain Bridge I, a SPAC, reported a significant net loss, a worsening accumulated deficit, and faces delisting from OTCQB, raising substantial doubt about its ability to continue as a going concern after its business combination agreement with Phytanix Bio was terminated.

Chain Bridge I filed an amended quarterly report, restating financials due to accounting errors, revealing a material weakness in internal controls, and announcing the termination of its business combination with Phytanix Bio, leading to Nasdaq delisting.

Chain Bridge I, a SPAC, reported a Q2 2025 net income but terminated its business combination agreement with Phytanix Bio, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I, a blank check company, reported a net loss of $363,640 for Q1 2025, terminated its business combination agreement with Phytanix Bio, and continues to face significant liquidity challenges and delisting from Nasdaq, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I, a blank check company, reported recurring losses, a working capital deficit, and delisting from Nasdaq to OTCID, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I, a blank check company, reported a net loss for 2024, a significant working capital deficit, and the termination of its proposed business combination with Phytanix Bio, leading to its delisting from Nasdaq and raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I's annual 10-K filing details the terms of its securities, including Class A and Class B ordinary shares, warrants, and related agreements, as the company seeks a business combination.

Chain Bridge I terminated its business combination agreement with Phytanix Bio and changed its independent registered public accounting firm from Frank, Rimerman & Co. LLP to RBSM, LLP.

Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid-based medicines, released its investor deck detailing its strategic vision and growth potential, coinciding with its planned merger with Chain Bridge I.

Chain Bridge I (CBRG) unveils a business combination agreement with Phytanix Bio to develop cannabinoid-based pharmaceuticals, focusing on bladder pain syndrome and treatment-resistant focal seizures.

Chain Bridge I (CBRG) will merge with Phytanix Bio, a pharmaceutical company focused on cannabinoid-based medicines, with the combined entity expected to trade on Nasdaq under the ticker PHYX.

Chain Bridge I, a SPAC, is seeking shareholder approval to extend its deadline to complete a business combination with CommLoan, Inc. until November 15, 2026, and to remove minimum net tangible asset requirements.

Chain Bridge I will be delisted from Nasdaq after failing to complete a business combination within the required timeframe, despite securing amendments to non-redemption agreements.

Chain Bridge I entered into non-redemption agreements to extend the deadline for completing a business combination and avoid liquidation.

Chain Bridge I has postponed its Extraordinary General Meeting to November 14, 2024, and extended the redemption deadline for Class A ordinary shares to November 12, 2024, to allow more time to engage with shareholders regarding a proposal to extend the company's lifespan.

Chain Bridge I announces an agreement with Fulton AC I LLC for up to $100,000 reimbursement to the Trust Account for dissolution expenses.

Chain Bridge I is seeking shareholder approval to extend the deadline for completing a business combination from November 15, 2024, to November 15, 2025, to allow more time to finalize its merger with Phytanix Bio.

Clear Street LLC has filed an amendment to its Schedule 13G, terminating its reporting obligation for Chain Bridge I common stock as its beneficial ownership no longer meets the 5% threshold.

Clear Street LLC has filed a Schedule 13G reporting a 15.5% beneficial ownership stake in Chain Bridge I common stock.

TD Securities and its affiliates report 0% beneficial ownership in Chain Bridge I, marking a full divestment.

Sandia Investment Management LP and Timothy J. Sichler have disclosed a passive beneficial ownership of 1.55% in Chain Bridge I's Class A Ordinary Shares.

TD Securities (USA) LLC, a subsidiary of Toronto Dominion Bank, has disclosed a 5% beneficial ownership stake in Chain Bridge I's Class A ordinary shares.

Sandia Investment Management LP and Timothy J. Sichler have reported a beneficial ownership of 8.3% of Chain Bridge I's Class A Ordinary Shares as of December 31, 2024, through a Schedule 13G filing.